NCT05317741View on ClinicalTrials.gov

SAD Study of IA-14069

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 23, 2021

Primary Completion Date

September 8, 2022

Study Completion Date

September 8, 2022

Conditions
Healthy
Interventions
DRUG

IA-14069

Subjects received IA-14069 tablet orally on Day 1.

DRUG

Placebo

Subjects received matching placebo tablet orally on Day 1.

Trial Locations (1)

66219

ICON plc., Lenexa

All Listed Sponsors
lead

ILAb Co., Ltd.

INDUSTRY

NCT05317741 - SAD Study of IA-14069 | Biotech Hunter | Biotech Hunter